Genentech is spending approximately US$750m on a new device fill-finish facility in Oregon. Commercial operations are not expected to begin until 2031.

Announced on 20 August, the investment will add capacity for advanced drug-delivery devices including prefilled syringes and autoinjectors. The timetable shows how long specialist pharmaceutical manufacturing capacity can take to bring into commercial operation, even when substantial capital is available.

That constraint is particularly important in sterile fill-finish and advanced therapies, where facilities, processes and quality systems can be difficult and time-consuming to replace once a programme is underway. The more specialised the requirement, the smaller the pool of manufacturing sites able to take it on.

Visiongain Top Takeaways

• Sterile capacity cannot be switched on quickly: new fill-finish lines require commissioning, qualification and validation before they can support commercial supply.
• Advanced-therapy capacity is not readily interchangeable: viral-vector platforms, cell-processing methods and analytical requirements narrow the pool of suitable manufacturing sites.
• The constraint is qualified fit, not headline capacity: sponsors need manufacturing that matches the product format, process and timetable.

Sterile Fill-Finish Takes Years to Bring Online

Visiongain estimates the global fill-finish manufacturing market at US$11.93bn in 2025 and forecasts a 10.1% CAGR from 2025 to 2035. Demand is being supported by biologics, vaccines and more complex injectable formats, while major new sterile capacity can require substantial capital and long lead times before commercial production begins.

Genentech’s Oregon project shows how large that commitment can be. The company is spending approximately US$750m to double the size of its Hillsboro facility and add high- and low-volume device filling, including prefilled syringes and autoinjectors. Commercial operations are expected in 2031.

CDMOs are investing too. Halo Pharma has committed US$45m to a sterile injectable line in New Jersey covering vials, prefilled syringes and cartridges. In August, Halo said the line was entering its final operational stages ahead of GMP qualification, with operation expected later in 2026.

Getting the equipment in place is only part of the job. Sterile lines still have to pass qualification and process validation before they can support routine manufacturing.

Capacity also has to be in the right format. A vial line cannot automatically absorb demand for prefilled syringes, cartridges or drug-device combinations, each of which can bring different equipment, component and validation requirements.

The real constraint is not total fill-finish capacity, but how much is available in the right format and ready when a product needs it.

Device Formats Change What Fill-Finish Capacity Has to Deliver

Prefilled syringes and autoinjectors change the manufacturing requirement as well as the patient experience. As drug-device combination products, they bring device performance, container compatibility and validation requirements alongside the sterile filling process.

Changing presentation later in development can require additional development, validation and regulatory work once the formulation and delivery system have been established.

Multi-format capacity gives sponsors more options, but only where the equipment, quality systems and technical expertise match the product. The relevant capacity is a line qualified for the presentation the programme needs.

Advanced Therapies Create a Different Capacity Problem

Visiongain forecasts the global cell and gene therapy manufacturing market to grow from US$13.7bn in 2026 to US$63.0bn by 2036, at a CAGR of 16.5%. Growth in the overall market, however, does not mean manufacturing demand is evenly distributed across technologies.

On 3 September, Northway Biotech opened a €61m cell-therapy and personalised-medicine CDMO facility in Vilnius. The 3,500 sq m centre provides up to 20 independent cGMP manufacturing lines, with its first customer programmes already secured.

Gene-therapy programmes bring different requirements. AAV and lentiviral-vector manufacturing can involve different production platforms, cell lines, purification processes and analytical assays, limiting how easily production can move between facilities.

Autologous therapies present another challenge. They are typically manufactured as patient-specific lots, so throughput depends on collection, transport, processing, release testing and delivery back to the treatment centre as well as the number of manufacturing suites available.

Advanced-therapy capacity is fragmented by modality, process and customer need. The market can have spare capacity in one area while suitable manufacturing remains constrained in another.

Specialist Capacity Still Carries Utilisation Risk

Advanced-therapy manufacturing can be constrained in one area and underused in another. The economics become particularly exposed when specialist facilities depend heavily on a small number of programmes or customers.

Cellares provided a recent example. In August, the cell-therapy manufacturer said it would resize its operations after Bristol Myers Squibb ended a major manufacturing partnership. BMS said the Cellares Cell Shuttle platform did not meet the requirements for commercial production of Breyanzi.

The case does not point to an industry-wide capacity surplus. It shows how quickly utilisation can change when specialist infrastructure depends heavily on individual programmes.

That puts more weight on the customer mix behind new capacity. The risk for CDMOs is not only whether they can build specialist capability, but whether enough viable programmes reach the facility and stay there long enough to support it.

Market Outlook: Scarcity and Overcapacity Can Coexist

Specialist pharmaceutical manufacturing cannot be read through total capacity alone. Sterile filling is fragmented by presentation and qualification status, while advanced-therapy capacity is divided further by modality, process and customer requirements.

The commercial risk runs in both directions. Sponsors can struggle to find qualified manufacturing when they need it, while CDMOs can be left with expensive specialist assets when programmes fail, move elsewhere or generate less demand than expected.

Format, modality, programme stage and customer concentration therefore matter as much as the size of the manufacturing footprint.

Visiongain Insight: Specialist manufacturing can be constrained and overbuilt at the same time. Shortages emerge when qualified capacity does not match the format, process or timing a programme requires, while specialised assets can remain underused when the programmes behind them fail to progress. The more useful question is not how much capacity exists, but where viable demand and qualified capability actually meet.

From Visiongain: Contract Manufacturing & CDMOs Hub

Visiongain’s Contract Manufacturing & CDMOs Hub brings together market analysis and forecasts covering pharmaceutical outsourcing, manufacturing investment, biologics, advanced therapies and supply-chain strategy.

Related reports include:

• Pharmaceutical Contract Manufacturing Market Report 2026-2036
• Cell & Gene Therapy Manufacturing Market Report 2026–2036
• Cell & Gene Therapy Market Report 2026–2036
• Vaccine Contract Manufacturing Market Report 2026-2036

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com